{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"44"}]}],"title":"Low Disease activity - Week 76 (n=108, 61, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"}]}],"title":"Remission - Week 76 (n=108, 61, 32)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"36"},{"groupId":"OG002","value":"56"}]}],"title":"Low Disease activity - Week 128 (n=79, 47, 18)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"39"}]}],"title":"Remission - Week 128 (n=79, 47, 18)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"61"},{"groupId":"OG002","value":"32"}],"units":"Participants"}],"description":"Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP (mg/L), and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \\<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.","groups":[{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"4 mg LY3009104 QD - Parts C and D"},{"description":"Received Placebo, or 1 mg, or 2 mg, or 4 mg LY3009104 in Part A.\n\nReceived 2 mg LY3009104 QD, or BID, or 4 mg LY3009104 QD in Part B.\n\nReceived 4 mg LY3009104 QD in Part C. During Part C, at Weeks 28 and 32, participants who met dose escalation criteria received 8 mg LY3009104 QD for the rest of the Part C.\n\nDose escalation criteria: ≥6 tender and 6 swollen joints based on the 28-joint count assessments and the clinical judgment of the investigator.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"4 to 8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"},{"description":"Received 8 mg LY3009104 QD in Parts A, B and C.\n\nReceived 4 mg LY3009104 QD in Part D.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"8 mg LY3009104 QD - Part C and 4 mg LY3009104 QD - Part D"}],"paramType":"NUMBER","populationDescription":"All participants who received study drug in Parts C and D and had DAS28-CRP evaluated at analysis time points.","reportingStatus":"POSTED","timeFrame":"Baseline through Weeks 76 and 128","title":"Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 76 and 128","type":"SECONDARY","unitOfMeasure":"percentage of participants"}